Neutrophil to lymphocyte ratio (NLR) impact on the progression-free survival and overall survival of multiple myeloma patients treated with high-dose chemotherapy and autologous stem cell transplantation

High-dose chemotherapy with autologous stem-cell transplantation (ASCT) remains the standard of care in multiple myeloma (MM) patients. This retrospective study aimed to assess the impact of neutrophil-to-lymphocyte ratio (NLR) and other complete blood count (CBC)-based predictors on PFS and OS of transplant-eligible MM patients. The CBC-based biomarkers were evaluated in a single-center cohort of 176 MM patients at three time points: at the diagnosis, the time of ASCT, and +100 d after ASCT. Univariable and multivariable Cox’s regression analyses and Kaplan–Meier estimate were used in statistical analysis. NLR at ASCT (HR 1.15, 95% CI: 1.05–1.26) and hemoglobin at ASCT (HR 0.80, 95% CI: 0.68–0.94) were independent factors influencing PFS. In the model for OS, the only statistically significant factors were NLR at ASCT (HR 1.15, 95% CI: 1.04–1.27), bortezomib administration prior to ASCT (HR 0.52, 95% CI: 0.33–0.83) and age at diagnosis (HR 1.03, 95% CI: 1.00–1.06). NLR at ASCT is an independent predictive factor in MM patients undergoing ASCT.